U.S. v. Glenmark Pharmaceuticals Inc., USA

Overview: 

Glenmark Pharmaceuticals Inc., USA is charged with knowingly entering into and engaging in a conspiracy to suppress and eliminate competition by agreeing to increase and maintain prices of pravastatin and other generic drugs sold in the United States. The charged conspiracy began at least as early as May 2013 and continued at least until December 2015.

For further information:

For questions about upcoming public hearings or victims’ rights, contact the Victim Hearing Coordinator in the Washington Criminal II Section.

Case Documents:

Superseding Indictment (July 14, 2020)

Information (June 30, 2020)

Case Open Date: 
Tuesday, June 30, 2020
Case Name: 
United States v. Glenmark Pharmaceuticals Inc., USA
Case Type: 
Criminal
Case Violation: 
Price Fixing - Horizontal
Tags: 
Pharmaceuticals
Generic Drugs
Pravastatin
Glenmark Pharmaceuticals
Inc.
USA
Market: 
Generic Drugs
Industry Code: 
Pharmaceutical and Medicine Manufacturing
Component: 
Antitrust Division
Updated August 10, 2020